Spyre Therapeutics (3920) Stock Overview
A clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
3920 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Spyre Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$61.50 |
| 52 Week High | US$65.00 |
| 52 Week Low | US$12.30 |
| Beta | 3.13 |
| 1 Month Change | 0.82% |
| 3 Month Change | 71.79% |
| 1 Year Change | 355.56% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 78.26% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3920 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -3.9% | 0.3% | 0.7% |
| 1Y | 355.6% | -8.2% | 2.0% |
Return vs Industry: 3920 exceeded the German Biotechs industry which returned -8.5% over the past year.
Return vs Market: 3920 exceeded the German Market which returned 2.2% over the past year.
Price Volatility
| 3920 volatility | |
|---|---|
| 3920 Average Weekly Movement | 10.4% |
| Biotechs Industry Average Movement | 8.4% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in DE Market | 13.1% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: 3920's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 3920's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 112 | Cameron Turtle | www.spyre.com |
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn’s disease); and SPY002 and SPY072 – anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs.
Spyre Therapeutics, Inc. Fundamentals Summary
| 3920 fundamental statistics | |
|---|---|
| Market cap | €5.47b |
| Earnings (TTM) | -€127.47m |
| Revenue (TTM) | n/a |
Is 3920 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3920 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$190.44m |
| Gross Profit | -US$190.44m |
| Other Expenses | -US$41.74m |
| Earnings | -US$148.70m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.71 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 3920 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/31 01:50 |
| End of Day Share Price | 2026/05/29 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Spyre Therapeutics, Inc. is covered by 24 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Colleen Kusy | Baird |
| Mayur Somaiya | BMO Capital Markets Equity Research |
| Julian Harrison | BTIG |